RAC1 as a Novel Therapeutic Target for Acute Liver Failure.
- Autores
- Bueloni, Bárbara; Fiore, Esteban Juan; Cantero, María José; Lameroli Mauriz, Lucia Ayelen; Atorrasagasti, María Catalina; Ciarlantini, Matías; Barquero, Andrea Alejandra; Gandolfi Donadío, Lucía; Ganiewich, Daiana; Orozco, Francisco; Fauda, Martín; Comin, Maria Julieta; Canbay, Ali; Bayo Fina, Juan Miguel; Mazzolini Rizzo, Guillermo Daniel
- Año de publicación
- 2025
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Background & Aims: The Rho GTPase RAC1 regulates key processes in acute liver failure (ALF), including oxidative stress and inflammation. We aimed to evaluate the therapeutic potential of RAC1 pharmacological inhibition in ALF.Methods: Ingenuity Pathway Analysis and gene ontology analysis were performed on transcriptomic datasets from ALF patients (GSE38941 and GSE80751). ALF was induced in mice using Concanavalin A, acetaminophen, or D-Galactosamine/Lipopolysaccharide (n = 10-21/group). The RAC1 pharmacological inhibitor 1D-142 was used in vivo and in vitro. Hepatocytes and macrophages, from primary cultures and cell lines, were analyzed. RNA-Seq data from ALF mouse livers (n = 3/group) were correlated with human datasets. Human liver explants (n = 6) were treated in vitro with 1D-142.Results: RAC1 emerges as an upstream regulator in human ALF samples correlating with immuneactivation and oxidative stress responses (p<0.05). Administration of 1D-142 ameliorated liver injury in murine ALF models when administered at early or late stages post-injury (p<0.05). 1D-142 treatment diminishes reactive oxygen species formation (p<0.01), inflammatory cell migration (p<0.001), cytokine production (p<0.05) and hepatocytes death (p<0.05). Liver transcriptomics revealed that RAC1 inhibition modulates key dysregulated pathways in ALF. Human ALF liver explants treated with 1D-142 showed reduced necrosis (p<0.05) and reduced expression of pro-inflammatory genes (p<0.01).Conclusions: RAC1 drives sterile inflammation and oxidative stress in ALF, and its pharmacologicalinhibition protects in murine models, supporting its potential as a therapeutic target forthis condition. Impact and implications: Acute liver failure (ALF) is a life-threatening condition with limited treatment options and is characterized by severe inflammation and oxidative stress. Our study provides strong scientific justification for targeting the RAC1 protein, demonstrating that its pharmacological inhibition with 1D-142 reduces liver injury, immune cell infiltration, and oxidative damage in murine models of ALF and in human liver explants. These findings identify RAC1 as a novel therapeutic target and provide translational support for its potential clinical application in ALF.RAC1-targeted therapy merits further studies in clinical settings.
Fil: Bueloni, Bárbara. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Fiore, Esteban Juan. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Cantero, María José. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Lameroli Mauriz, Lucia Ayelen. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Atorrasagasti, María Catalina. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Ciarlantini, Matías. Instituto Nacional de Tecnología Industrial; Argentina
Fil: Barquero, Andrea Alejandra. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Gandolfi Donadío, Lucía. Instituto Nacional de Tecnología Industrial; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Ganiewich, Daiana. Fundación Instituto Leloir; Argentina
Fil: Orozco, Francisco. Universidad Austral. Hospital Universitario Austral; Argentina
Fil: Fauda, Martín. Universidad Austral. Hospital Universitario Austral; Argentina
Fil: Comin, Maria Julieta. Instituto Nacional de Tecnología Industrial; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Canbay, Ali. Ruhr Universität Bochum; Alemania
Fil: Bayo Fina, Juan Miguel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina - Materia
-
RHO GTPases
molecular inhibitors
hepatocyte apoptosis
HBV associated liver failure - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/270957
Ver los metadatos del registro completo
id |
CONICETDig_12267febf3dc3db2dc8e50d72c3534c3 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/270957 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
RAC1 as a Novel Therapeutic Target for Acute Liver Failure.Bueloni, BárbaraFiore, Esteban JuanCantero, María JoséLameroli Mauriz, Lucia AyelenAtorrasagasti, María CatalinaCiarlantini, MatíasBarquero, Andrea AlejandraGandolfi Donadío, LucíaGaniewich, DaianaOrozco, FranciscoFauda, MartínComin, Maria JulietaCanbay, AliBayo Fina, Juan MiguelMazzolini Rizzo, Guillermo DanielRHO GTPasesmolecular inhibitorshepatocyte apoptosisHBV associated liver failurehttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Background & Aims: The Rho GTPase RAC1 regulates key processes in acute liver failure (ALF), including oxidative stress and inflammation. We aimed to evaluate the therapeutic potential of RAC1 pharmacological inhibition in ALF.Methods: Ingenuity Pathway Analysis and gene ontology analysis were performed on transcriptomic datasets from ALF patients (GSE38941 and GSE80751). ALF was induced in mice using Concanavalin A, acetaminophen, or D-Galactosamine/Lipopolysaccharide (n = 10-21/group). The RAC1 pharmacological inhibitor 1D-142 was used in vivo and in vitro. Hepatocytes and macrophages, from primary cultures and cell lines, were analyzed. RNA-Seq data from ALF mouse livers (n = 3/group) were correlated with human datasets. Human liver explants (n = 6) were treated in vitro with 1D-142.Results: RAC1 emerges as an upstream regulator in human ALF samples correlating with immuneactivation and oxidative stress responses (p<0.05). Administration of 1D-142 ameliorated liver injury in murine ALF models when administered at early or late stages post-injury (p<0.05). 1D-142 treatment diminishes reactive oxygen species formation (p<0.01), inflammatory cell migration (p<0.001), cytokine production (p<0.05) and hepatocytes death (p<0.05). Liver transcriptomics revealed that RAC1 inhibition modulates key dysregulated pathways in ALF. Human ALF liver explants treated with 1D-142 showed reduced necrosis (p<0.05) and reduced expression of pro-inflammatory genes (p<0.01).Conclusions: RAC1 drives sterile inflammation and oxidative stress in ALF, and its pharmacologicalinhibition protects in murine models, supporting its potential as a therapeutic target forthis condition. Impact and implications: Acute liver failure (ALF) is a life-threatening condition with limited treatment options and is characterized by severe inflammation and oxidative stress. Our study provides strong scientific justification for targeting the RAC1 protein, demonstrating that its pharmacological inhibition with 1D-142 reduces liver injury, immune cell infiltration, and oxidative damage in murine models of ALF and in human liver explants. These findings identify RAC1 as a novel therapeutic target and provide translational support for its potential clinical application in ALF.RAC1-targeted therapy merits further studies in clinical settings.Fil: Bueloni, Bárbara. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; ArgentinaFil: Fiore, Esteban Juan. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; ArgentinaFil: Cantero, María José. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; ArgentinaFil: Lameroli Mauriz, Lucia Ayelen. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; ArgentinaFil: Atorrasagasti, María Catalina. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; ArgentinaFil: Ciarlantini, Matías. Instituto Nacional de Tecnología Industrial; ArgentinaFil: Barquero, Andrea Alejandra. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Gandolfi Donadío, Lucía. Instituto Nacional de Tecnología Industrial; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Ganiewich, Daiana. Fundación Instituto Leloir; ArgentinaFil: Orozco, Francisco. Universidad Austral. Hospital Universitario Austral; ArgentinaFil: Fauda, Martín. Universidad Austral. Hospital Universitario Austral; ArgentinaFil: Comin, Maria Julieta. Instituto Nacional de Tecnología Industrial; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Canbay, Ali. Ruhr Universität Bochum; AlemaniaFil: Bayo Fina, Juan Miguel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; ArgentinaFil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; ArgentinaElsevier2025-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/270957Bueloni, Bárbara; Fiore, Esteban Juan; Cantero, María José; Lameroli Mauriz, Lucia Ayelen; Atorrasagasti, María Catalina; et al.; RAC1 as a Novel Therapeutic Target for Acute Liver Failure.; Elsevier; JHEP Reports; 8-2025; 1-432589-5559CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S2589555925002265info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jhepr.2025.101547info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:41:41Zoai:ri.conicet.gov.ar:11336/270957instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:41:42.154CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
RAC1 as a Novel Therapeutic Target for Acute Liver Failure. |
title |
RAC1 as a Novel Therapeutic Target for Acute Liver Failure. |
spellingShingle |
RAC1 as a Novel Therapeutic Target for Acute Liver Failure. Bueloni, Bárbara RHO GTPases molecular inhibitors hepatocyte apoptosis HBV associated liver failure |
title_short |
RAC1 as a Novel Therapeutic Target for Acute Liver Failure. |
title_full |
RAC1 as a Novel Therapeutic Target for Acute Liver Failure. |
title_fullStr |
RAC1 as a Novel Therapeutic Target for Acute Liver Failure. |
title_full_unstemmed |
RAC1 as a Novel Therapeutic Target for Acute Liver Failure. |
title_sort |
RAC1 as a Novel Therapeutic Target for Acute Liver Failure. |
dc.creator.none.fl_str_mv |
Bueloni, Bárbara Fiore, Esteban Juan Cantero, María José Lameroli Mauriz, Lucia Ayelen Atorrasagasti, María Catalina Ciarlantini, Matías Barquero, Andrea Alejandra Gandolfi Donadío, Lucía Ganiewich, Daiana Orozco, Francisco Fauda, Martín Comin, Maria Julieta Canbay, Ali Bayo Fina, Juan Miguel Mazzolini Rizzo, Guillermo Daniel |
author |
Bueloni, Bárbara |
author_facet |
Bueloni, Bárbara Fiore, Esteban Juan Cantero, María José Lameroli Mauriz, Lucia Ayelen Atorrasagasti, María Catalina Ciarlantini, Matías Barquero, Andrea Alejandra Gandolfi Donadío, Lucía Ganiewich, Daiana Orozco, Francisco Fauda, Martín Comin, Maria Julieta Canbay, Ali Bayo Fina, Juan Miguel Mazzolini Rizzo, Guillermo Daniel |
author_role |
author |
author2 |
Fiore, Esteban Juan Cantero, María José Lameroli Mauriz, Lucia Ayelen Atorrasagasti, María Catalina Ciarlantini, Matías Barquero, Andrea Alejandra Gandolfi Donadío, Lucía Ganiewich, Daiana Orozco, Francisco Fauda, Martín Comin, Maria Julieta Canbay, Ali Bayo Fina, Juan Miguel Mazzolini Rizzo, Guillermo Daniel |
author2_role |
author author author author author author author author author author author author author author |
dc.subject.none.fl_str_mv |
RHO GTPases molecular inhibitors hepatocyte apoptosis HBV associated liver failure |
topic |
RHO GTPases molecular inhibitors hepatocyte apoptosis HBV associated liver failure |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Background & Aims: The Rho GTPase RAC1 regulates key processes in acute liver failure (ALF), including oxidative stress and inflammation. We aimed to evaluate the therapeutic potential of RAC1 pharmacological inhibition in ALF.Methods: Ingenuity Pathway Analysis and gene ontology analysis were performed on transcriptomic datasets from ALF patients (GSE38941 and GSE80751). ALF was induced in mice using Concanavalin A, acetaminophen, or D-Galactosamine/Lipopolysaccharide (n = 10-21/group). The RAC1 pharmacological inhibitor 1D-142 was used in vivo and in vitro. Hepatocytes and macrophages, from primary cultures and cell lines, were analyzed. RNA-Seq data from ALF mouse livers (n = 3/group) were correlated with human datasets. Human liver explants (n = 6) were treated in vitro with 1D-142.Results: RAC1 emerges as an upstream regulator in human ALF samples correlating with immuneactivation and oxidative stress responses (p<0.05). Administration of 1D-142 ameliorated liver injury in murine ALF models when administered at early or late stages post-injury (p<0.05). 1D-142 treatment diminishes reactive oxygen species formation (p<0.01), inflammatory cell migration (p<0.001), cytokine production (p<0.05) and hepatocytes death (p<0.05). Liver transcriptomics revealed that RAC1 inhibition modulates key dysregulated pathways in ALF. Human ALF liver explants treated with 1D-142 showed reduced necrosis (p<0.05) and reduced expression of pro-inflammatory genes (p<0.01).Conclusions: RAC1 drives sterile inflammation and oxidative stress in ALF, and its pharmacologicalinhibition protects in murine models, supporting its potential as a therapeutic target forthis condition. Impact and implications: Acute liver failure (ALF) is a life-threatening condition with limited treatment options and is characterized by severe inflammation and oxidative stress. Our study provides strong scientific justification for targeting the RAC1 protein, demonstrating that its pharmacological inhibition with 1D-142 reduces liver injury, immune cell infiltration, and oxidative damage in murine models of ALF and in human liver explants. These findings identify RAC1 as a novel therapeutic target and provide translational support for its potential clinical application in ALF.RAC1-targeted therapy merits further studies in clinical settings. Fil: Bueloni, Bárbara. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina Fil: Fiore, Esteban Juan. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina Fil: Cantero, María José. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina Fil: Lameroli Mauriz, Lucia Ayelen. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina Fil: Atorrasagasti, María Catalina. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina Fil: Ciarlantini, Matías. Instituto Nacional de Tecnología Industrial; Argentina Fil: Barquero, Andrea Alejandra. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Gandolfi Donadío, Lucía. Instituto Nacional de Tecnología Industrial; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Ganiewich, Daiana. Fundación Instituto Leloir; Argentina Fil: Orozco, Francisco. Universidad Austral. Hospital Universitario Austral; Argentina Fil: Fauda, Martín. Universidad Austral. Hospital Universitario Austral; Argentina Fil: Comin, Maria Julieta. Instituto Nacional de Tecnología Industrial; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Canbay, Ali. Ruhr Universität Bochum; Alemania Fil: Bayo Fina, Juan Miguel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina Fil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina |
description |
Background & Aims: The Rho GTPase RAC1 regulates key processes in acute liver failure (ALF), including oxidative stress and inflammation. We aimed to evaluate the therapeutic potential of RAC1 pharmacological inhibition in ALF.Methods: Ingenuity Pathway Analysis and gene ontology analysis were performed on transcriptomic datasets from ALF patients (GSE38941 and GSE80751). ALF was induced in mice using Concanavalin A, acetaminophen, or D-Galactosamine/Lipopolysaccharide (n = 10-21/group). The RAC1 pharmacological inhibitor 1D-142 was used in vivo and in vitro. Hepatocytes and macrophages, from primary cultures and cell lines, were analyzed. RNA-Seq data from ALF mouse livers (n = 3/group) were correlated with human datasets. Human liver explants (n = 6) were treated in vitro with 1D-142.Results: RAC1 emerges as an upstream regulator in human ALF samples correlating with immuneactivation and oxidative stress responses (p<0.05). Administration of 1D-142 ameliorated liver injury in murine ALF models when administered at early or late stages post-injury (p<0.05). 1D-142 treatment diminishes reactive oxygen species formation (p<0.01), inflammatory cell migration (p<0.001), cytokine production (p<0.05) and hepatocytes death (p<0.05). Liver transcriptomics revealed that RAC1 inhibition modulates key dysregulated pathways in ALF. Human ALF liver explants treated with 1D-142 showed reduced necrosis (p<0.05) and reduced expression of pro-inflammatory genes (p<0.01).Conclusions: RAC1 drives sterile inflammation and oxidative stress in ALF, and its pharmacologicalinhibition protects in murine models, supporting its potential as a therapeutic target forthis condition. Impact and implications: Acute liver failure (ALF) is a life-threatening condition with limited treatment options and is characterized by severe inflammation and oxidative stress. Our study provides strong scientific justification for targeting the RAC1 protein, demonstrating that its pharmacological inhibition with 1D-142 reduces liver injury, immune cell infiltration, and oxidative damage in murine models of ALF and in human liver explants. These findings identify RAC1 as a novel therapeutic target and provide translational support for its potential clinical application in ALF.RAC1-targeted therapy merits further studies in clinical settings. |
publishDate |
2025 |
dc.date.none.fl_str_mv |
2025-08 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/270957 Bueloni, Bárbara; Fiore, Esteban Juan; Cantero, María José; Lameroli Mauriz, Lucia Ayelen; Atorrasagasti, María Catalina; et al.; RAC1 as a Novel Therapeutic Target for Acute Liver Failure.; Elsevier; JHEP Reports; 8-2025; 1-43 2589-5559 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/270957 |
identifier_str_mv |
Bueloni, Bárbara; Fiore, Esteban Juan; Cantero, María José; Lameroli Mauriz, Lucia Ayelen; Atorrasagasti, María Catalina; et al.; RAC1 as a Novel Therapeutic Target for Acute Liver Failure.; Elsevier; JHEP Reports; 8-2025; 1-43 2589-5559 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S2589555925002265 info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jhepr.2025.101547 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier |
publisher.none.fl_str_mv |
Elsevier |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844614448381165568 |
score |
13.070432 |